What is the primary goal of the TIRF program concerning opioids?

The primary goal of the TIRF (Transmucosal Immediate-Release Fentanyl) program is to prevent misuse of potent opioid medications. The TIRF program was established to ensure that these medications are prescribed and used appropriately, particularly because of their high risk for abuse and potential for overdose.

TIRF medications are specific formulations of fentanyl that are effective for treating breakthrough pain in patients who are already on a stable dose of around-the-clock opioid therapy. Given the risks associated with these strong opioids, the program emphasizes the importance of educating healthcare providers and patients on safe use and proper storage to reduce the likelihood of misuse, accidental exposure, and diversion.

By focusing on misuse prevention, the program aims to promote safe prescribing practices and improve patient outcomes while minimizing the risks associated with opioid therapy. This is crucial in the context of the ongoing opioid crisis, where misuse and addiction have become critical public health issues.